2E9 Stock Chart & Stats
€0.09
<€0.01(11.11%)
At close: 4:00 PM EDT
€0.09
<€0.01(11.11%)
Day’s Range― - ―
52-Week Range€0.01 - €0.11
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€34.02M
Enterprise Value€317.65
Total Cash (Recent Filing)€127.64M
Total Debt (Recent Filing)€866.00K
Price to Earnings (P/E)―
Beta1.13
Next Earnings
Nov 12, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.26
Shares Outstanding340,813,200
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)1.00
Price to Sales (P/S)13.68
P/FCF Ratio-4.11
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.02
Revenue Forecast (FY)€1.60M
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageNear-zero leverage limits interest and refinancing risk, preserving financial flexibility while the company funds research, commercialization, and market expansion in a capital-intensive biotech model.
Commercialized Vaccine PlatformAn existing marketed canine vaccine provides a commercial foundation, customer access through veterinary channels, and a platform from which Intervacc can build recurring animal-health sales and broader product adoption.
Historical Revenue ExpansionEarlier multi-year revenue expansion indicates that the product and commercialization strategy have generated demand at points in the cycle, providing evidence of market potential despite the recent deterioration in sales.
Bears Say
Persistent UnprofitabilitySustained losses and negative gross profit show that current pricing, scale, or production economics are insufficient to support the business, weakening internal funding capacity and making a durable path to profitability uncertain.
Continued Cash BurnPersistent operating and free-cash-flow deficits mean the company must continue relying on its cash reserves or external financing to fund operations, increasing dilution and execution risk if commercialization does not improve.
Recent Revenue ContractionThe latest revenue decline suggests that product uptake or market expansion has weakened after earlier growth, reducing operating leverage and making it harder to absorb fixed development and commercialization costs.
2E9 FAQ
What was Intervacc AB’s price range in the past 12 months?
Intervacc AB lowest stock price was €0.01 and its highest was €0.11 in the past 12 months.
What is Intervacc AB’s market cap?
Intervacc AB’s market cap is €34.02M.
When is Intervacc AB’s upcoming earnings report date?
Intervacc AB’s upcoming earnings report date is Nov 12, 2026 which is in 82 days.
How were Intervacc AB’s earnings last quarter?
Intervacc AB released its earnings results on Aug 20, 2026. The company reported -€0.005 earnings per share for the quarter, missing the consensus estimate of -€0.005 by >-€0.001.
Is Intervacc AB overvalued?
According to Wall Street analysts Intervacc AB’s price is currently Overvalued.
Does Intervacc AB pay dividends?
Intervacc AB does not currently pay dividends.
What is Intervacc AB’s EPS estimate?
Intervacc AB’s EPS estimate is >-0.01.
How many shares outstanding does Intervacc AB have?
Intervacc AB has 340,813,200 shares outstanding.
What happened to Intervacc AB’s price movement after its last earnings report?
Intervacc AB reported an EPS of -€0.005 in its last earnings report, missing expectations of -€0.005. Following the earnings report the stock price went down -3.571%.
Which hedge fund is a major shareholder of Intervacc AB?
Currently, no hedge funds are holding shares in DE:2E9
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Intervacc AB
Intervacc AB (publ) is a Swedish biotechnology company primarily engaged in the research and development of innovative vaccines designed to combat bacterial infections in animal health. The firm's vaccine pipeline targets various animals, including horses, piglets, and dairy cows, with its key product, Strangvac, specifically developed to prevent equine strangles. Beyond its current offerings, Intervacc is also advancing vaccines against Streptococcus suis and Staphylococcus aureus infections. In addition to vaccine development, the company distributes veterinary medicines and provides essential diagnostic services in veterinary bacteriology to clinics and stud farms. Headquartered in Hägersten, Sweden, Intervacc serves customers across the Nordic countries and the Baltic states.
Technical Analysis
Xbrane Biopharma AB
―
Elicera Therapeutics AB
―
Ascelia Pharma AB
―
IRLAB Therapeutics AB Class A
―
Immunicum AB
―